Dr. Reddy’s Labs launches Icosapent Ethyl Capsules

The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

79
Medicine Capsule
Picture: Pixabay

Dr Reddy’s Laboratories Ltd announced the launch of the US Food and Drug Administration (USFDA) approved icosapent ethyl capsules, 1 gram

Dr Reddy’s icosapent ethyl capsules, 1 gram is approved for the indication of as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (= 500 mg/dL) hypertriglyceridemia.

The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Dr Reddy’s icosapent ethylis available in 1 gram capsules in bottle count size of 120’s count.

Cadila Pharma launches Posaconazole to treat fungal diseases

Cipla launches Vitamin C Chewable Tablets with Gold Supplement

Glenmark launches drug to treat Pulmonary disease in UK

Alkem launches Drug for Epilepsy treatment in India

Black Fungus: Mankind Pharma launches drug for treatment

Black fungus: SP Accure Labs launches Amphotericin B emulsion

Applications Forms: All types of Clinical Trials

Govt invites applications to manufacture Medical Device under PLI scheme

IPC to revise draft chapter on alternative Rapid Microbiological methods

European Commission approves Empagliflozin to treat heart failure

Synthetic Kidney can be created: Stem cell researchers

Common antibiotic useful in recovery of TB patients ?

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner